Andrew Moreno

DocwireNews

In a recent study, researchers assessed the clinical performance of ivosidenib for treatment of mutant isocitrate dehydrogenase 1 (mIDH1) myelodysplastic syndrome (MDS) using the International Working Group (IWG) 2023 MDS criteria. Based on these criteria, they found that ivosidenib produced a high overall response rate (ORR) in this setting.
The researchers also used this study to compare the assessments done using the 2023 MDS criteria with those of the 2006 criteria.
“By eliminating [the IWG 2006 marrow complete remission (CR) category] and assessing response in a high-risk population with [less than] 5% blasts, IWG 2023 criteria accurately capture the clinical benefit of ivosidenib in relapsed or refractory MDS,” wrote lead author Yazan Madanat, MD, of the University of Texas Southwestern Medical Center, Dallas.
The researchers presented their findings at the 66th American Society of Hematology Annual Meeting &amp; Exposition in San Diego, California.
The study had a cohort of 19 patients with MDS previously treated with standard-of-care therapy. The patients had a median age of 73 years, and 78.9% had prior hypomethylating therapy. Eighteen patients had efficacy-evaluable data. The cohort received oral ivosidenib 500 mg daily through 28-day cycles.
In their comparison of assessments done with the IWG 2023 versus the 2006 criteria, the investigators’ IWG 2023 assessment applied a composite CR category. This composite CR combined CR with CR equivalent, CR with limited count recovery, and CR with partial hematologic recovery.
According to IWG 2006 criteria, the cohort had a CR plus partial remission (PR) rate of 38.9%, with CR achieved in all responders. By IWG 2023 criteria, the composite CR plus PR rate was 66.7%. By IWG 2006 criteria, the cohort had an ORR of 83.3%, and by IWG 2023 criteria, an ORR of 72.2%
Eight patients who had been classified as having marrow CR by IWG 2006 criteria were reclassified by IWG 2023 criteria as follows: one with CR, four with CR with limited count recovery, one with hematologic improvement, and two with no response. Median time to composite CR was 1.58 months, and median duration was not reached.
Transfusion independence was achieved by five of seven patients who required red blood cell transfusion at baseline and by three of four patients who required platelet transfusion. The median time to either independence type was 2.64 months for patients with composite CR. Ten of 12 patients with composite CR had or maintained transfusion independence during the study. The median duration of transfusion independence was not reached.
“While comparison of survival outcomes between IWG 2006 and IWG 2023 is limited by the small sample size, a similar trend with response-dependent EFS and OS outcomes was observed,” Dr. Madanat concluded.
Reference
Madanat YF, Fathi AT, Garcia-Manero G, et al. Ivosidenib in patients with mutant isocitrate dehydrogenase 1 (mIDH1) relapsed/refractory myelodysplastic syndromes: Update of the phase 1 substudy per the International Working Group 2023 response criteria. Abstract #1841. Presented at the 66th American Society of Hematology Annual Meeting and Exposition; December 7-10, 2024; San Diego, California.

Cecilia Brown

FDA Issues Complete Response Letter for Subcutaneous Amivantamab in NSCLC

Non-Small Cell Lung Cancer

IWG 2023, 2006 MDS Criteria Assessments of Ivosidenib for mIDH1 Disease Compared

ASH 2024

Venetoclax, Cladribine, Idarubicin, Cytarabine Regimen Evaluated in AML, High-Risk MDS

Latest News

Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe